Physician profile
Mark K Aasen
NPI 1184609356
$7,445.37
in general payments reported to CMS, 2019-2025
13 companies · $196 in 2025
The $196 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $208 · 2020: $20.71 · 2021: $222 · 2022: $168 · 2023: $6,015 · 2024: $616 · 2025: $196.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,000 · Food and Beverage: $1,611 · Travel and Lodging: $216.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,000.00 |
| Food and Beverage | $1,611.41 |
| Travel and Lodging | $215.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Si-Bone, INC. | $5,504.37 | 2022-2023 | |
| Nevro Corp. | $792.21 | 2019-2024 | Senza |
| Curonix LLC | $372.06 | 2024-2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Collegium Pharmaceutical, INC. | $192.87 | 2021-2024 | Belbuca, Xtampza |
| Janssen Pharmaceuticals, INC | $150.00 | 2024 | Spravato |
| Spinal Simplicity, LLC | $102.29 | 2025 | Ha Minuteman G3-R |
| Boston Scientific Corporation | $96.78 | 2021 | |
| Abbvie INC. | $74.74 | 2022-2025 | Ubrelvy |
| Medtronic, INC. | $54.40 | 2022-2023 | Synchromedii |
| Abbott Laboratories | $44.83 | 2021-2025 | Proclaim |
| Neuronetics, INC. | $29.92 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $19.47 | 2022 | |
| Assertio Therapeutics, INC. | $11.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Aasen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.